#16
|
|||
|
|||
Âëàä! Ïîäïèñûâàþñü ïîä êàæäûì òâîèì ñëîâîì! Âñå ýòî ïðîõîäèë ñàì.
|
#17
|
||||
|
||||
Ãîâîðÿò, â Ìîñêâå êóð äîÿò, à ìû ïîøëè è ñèñåê íå íàøëè! (Íàðîäíàÿ ïîñëîâèöà)
FDA â ïîñëåäíåå âðåìÿ îäîáðÿåò âñ¸ ÷òî íóæíî è íå íóæíî. À ìíå âîò òàêàÿ ðàññûëî÷êà íà ïî÷òó ïðèøëà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïîïàõèâàåò ãðàíäèîçíûì çàêàçîì â àäðåñ FDA. Áàáîñû áåøåíûå! Íàäî î÷åíü õîðîøî ôèëüòðîâàòü âñå ýòè "ãîâîðÿò". |
#18
|
||||
|
||||
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Fassnacht-Riederle H , Becker M, Graf N, Michels S.
Author information Abstract PURPOSE: at 4-week intervals in patients with neovascular AMD showing an "insufficient anatomic response" to prior anti-VEGF therapy with ranibizumab or bevacizumab. METHODS: eyes that had received at least three intravitreal 0.5 mg ranibizumab or 1.25 mg bevacizumab injections over a period of no more than 4 months prior to switching to aflibercept. In addition, the selected eyes had to have evidence of persisting or increasing sub- or intraretinal fluid, observed in optical coherence tomography (OCT). All patients received a loading dose of three intravitreal 2 mg aflibercept injections at 4-week intervals. Evaluation included central retinal thickness (CRT) and maximum pigment epithelium (PED) height measured by spectral domain OCT and best-corrected visual acuity (BCVA) prior to the switch of therapy and 4 weeks after the third aflibercept injection. RESULTS: A significant reduction of mean CRT (-39 μm; p < 0.001) and maximum PED height (-46 μm; p < 0.001) as found 4 weeks after the third aflibercept injection. Eighty-two out of 96 eyes (85 %) had a PED just prior to switching to aflibercept. There was an improvement in BCVA of 1.9 letters 4 weeks after the last aflibercept injection; the vision gain, however, did not reach statistical significance (p = 0.061). The further analysis did not show any correlation of the change in CRT, maximum PED, and BCVA with the number of prior anti-VEGF treatments. CONCLUSION: Retinal edema and PEDs regressed significantly after switching to aflibercept in patients insufficiently responding to prior therapy with ranibizumab or bevacizumab. No correlation could be found with regard to the number of prior treatments. |
#19
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#20
|
||||
|
||||
ß óæå è áóðæóéñêèì äîêàçàòåëüñòâàì ñòàë âåðèòü ïîïîëàì. Äîôèãà ïîäòàñîâîê.
|
#22
|
||||
|
||||
È ñîáñòâåííûå ñîñóäû óíè÷òîæèøü. Åñëè áåç ìåðû ïîâòîðÿòü.
|
|